Ranibizumab intravítreo en el tratamiento de membrana neovascular subretiniana en un caso de coroidopatía puntata interna

Jiménez, Beatriz; Pinilla, Isabel; Cristobal, Ja; Minguez, E; Romero, Daniel; Cruz, N; Peiro, C

doi:10.1016/j.oftal.2012.11.008

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several case reports and short case series have provided evidence of the benefits of anti-VEGF therapy for treating CNV associated with PIC, both with and without concomitant treatment (i.e., oral corticoids) to manage inflammatory lesions. These studies have been mainly conducted with ranibizumab [1, 9, 10, 11, 12], one of the first anti-VEGF agents licensed for intravitreal use, but also with bevacizumab [13, 14, 15], which is often used off-label in intravitreal injections. Given the lack of guidance regarding how to best use these anti-VEGF agents in off-label conditions, there is a lack of uniformity in the different reports.…”

Section: Discussion/conclusionmentioning

confidence: 99%

“…Given the lack of guidance regarding how to best use these anti-VEGF agents in off-label conditions, there is a lack of uniformity in the different reports. Hence, some studies report using an initial loading dose (1 injection every 4 weeks for 3 months) of bevacizumab [13] or ranibizumab [10] with 6 or 12 months of follow-up, respectively. Other studies report the effectiveness of a single injection of either ranibizumab [9] or bevacizumab [15] with visual and anatomic benefits lasting during 8 and even 24 months of follow-up, respectively.…”

Section: Discussion/conclusionmentioning

confidence: 99%

See 1 more Smart Citation

Two-Year Outcome of Aflibercept for the Treatment of Choroidal Neovascularization in Punctate Inner Choroidopathy

Arrevola¹,

Acero²,

Peral³

2019

Case Rep Ophthalmol

View full text Add to dashboard Cite

Punctate inner choroidopathy (PIC) is a rare inflammatory chorioretinopathy that predominantly affects young myopic women. Visual prognosis is generally good, but occurrence of choroidal neovascularization (CNV) is common and may be vision threatening. Case reports and short case series support the effectiveness of intravitreal anti-vascular endothelial growth factor (VEGF) agents (ranibizumab and bevacizumab) for CNV associated with PIC given their anti-angiogenic and anti-inflammatory effects. Evidence concerning aflibercept, a more recent intravitreal anti-VEGF, is limited to a single case report. In this case report, we illustrate the case of a 43-year-old myopic woman presenting with visual acuity loss and distortion in the right eye over the last 5 days in whom CNV associated with PIC was diagnosed. Treatment with 1 injection per month of intravitreal aflibercept for 2 months and full-dose oral prednisone for 1 week, being tapered afterwards, improved visual acuity and resolved CNV, with benefits lasting up to 24 months.

show abstract

Section: Discussion/conclusionmentioning

confidence: 99%

Section: Discussion/conclusionmentioning

confidence: 99%

Two-Year Outcome of Aflibercept for the Treatment of Choroidal Neovascularization in Punctate Inner Choroidopathy

Arrevola¹,

Acero²,

Peral³

2019

Case Rep Ophthalmol

View full text Add to dashboard Cite

show abstract

Outcomes in PIC-Related CNV: Pooled Analysis of Individual Participant Data

Zaslavsky

Park

Mcinnis

et al. 2022

Ocular Immunology and Inflammation

View full text Add to dashboard Cite

Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Peng

Zhang

et al. 2017

BMC Ophthalmol

View full text Add to dashboard Cite

BackgroundTo evaluate the efficacy and safety of intravitreal conbercept (KH902) as the primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy.MethodsThis study was a retrospective, consecutive, observational case series. We reviewed medical records of 16 eyes (16 patients) with naive subfoveal or juxtafoveal choroidal neovascularization secondary to punctuate inner choroidopathy that were treated with intravitreal conbercept injections. All patients completed at least six months of follow-up. Best-corrected visual acuity (BCVA) was measured, and anatomical features were assessed with fluorescein angiography, indocyanine green angiography, and optical coherence tomography.ResultsAt the month-6 follow-up visit, best-corrected visual acuity improved from 0.70 ± 0.36 (with approximate Snellen equivalent of 20/100) to 0.44 ± 0.25 (20/50 in Snellen) logarithm of the minimum angle of resolution (logMAR) (P = 0.003). Mean improvement of vision was 2.6 lines, with 50% treated eyes (8 eyes of 16) showing an improvement of ≥3 lines and 62.5% (10 eyes of 16), obtaining an improvement of ≥2 lines; all 16 eyes had stable or improved vision. Mean central retinal thickness decreased from 294.94 ± 102.68 μm to 206.56 ± 61.71 μm (P = 0.005). Fifteen eyes (93.75%) showed absence of CNV leakage at the end of the study period. No conbercrept-related systemic or ocular adverse events were observed.ConclusionIntravitreal injection of conbercept significantly improved visual and anatomical outcomes in choroidal neovascularization secondary to punctate inner choroidopathy over a 6-month follow-up period.Trial registration ISRCTN85678307, retrospectively registered on May 11, 2017.

show abstract

Ranibizumab intravítreo en el tratamiento de membrana neovascular subretiniana en un caso de coroidopatía puntata interna

Cited by 4 publications

References 5 publications

Two-Year Outcome of Aflibercept for the Treatment of Choroidal Neovascularization in Punctate Inner Choroidopathy

Two-Year Outcome of Aflibercept for the Treatment of Choroidal Neovascularization in Punctate Inner Choroidopathy

Outcomes in PIC-Related CNV: Pooled Analysis of Individual Participant Data

Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Contact Info

Product

Resources

About